Aug 24,2023

TEAM OF 50 INDIVIDUALS IMPACTED BY DIABETES PREPARE FOR THE 2023 TCS NEW YORK CITY MARATHON

On November 5, diabetes nonprofit Beyond Type 1 will join more than 550 official charity partners and philanthropists raising awareness and funds while participating in the world's largest marathon, the TCS New York City Marathon. This year, the organization is expanding its 50-person team, Beyond Type Run, to include people living with type 1 or type 2 diabetes, as well as caregivers to those living with diabetes. Dexcom and Tandem Diabetes Care are presenting sponsors of Beyond Type Run for a fourth consecutive year. The marathon runners who are using a Dexcom continuous glucose monitor and a Tandem Diabetes Care insulin pump can monitor their glucose levels and dose the proper amount of insulin without fingersticks and insulin shots – helping them spend more time in their target glucose range and keeping their focus on competing at their best.

View Analyst & Ambassador Comments
Go to original news
Aug 24,2023

Dario Publishes New Research Demonstrating Greater Engagemenet and Improved Clinical Outcomes Sustainable for Two Years

DarioHealth announced new research presented at the ADCES23 Annual Conference held earlier this month in Houston, Texas. The new research demonstrates Dario's ability to sustainably improve health outcomes for users with diabetes over a two-year period. The latest research analyzed the data of 119,482 Dario members to understand the relationship between improving engagement and health outcomes. The results showed that during the two years of data analyzed in the research study, users improved engagement 29% over two years. Users with high-risk diabetes demonstrated reductions in their high-blood glucose reading ratios and monthly average glucose that correlated with increased engagement.

CLINICAL STUDY

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
Aug 23,2023

Welldoc Receives 11th 510(k) Clearance from FDA for Award-Winning Diabetes Platform BlueStar

Welldoc today announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar . This clearance immediately follows Welldoc’s 10th 510(k) clearance announcement earlier this month, solidifying the company’s continued leadership in chronic care innovation. Welldoc’s latest 510(k) enables BlueStar to provide bolus insulin dose recommendations based on the most recent glucose reading and rate of change from a compatible continuous glucose monitoring (CGM) device. This feature enhances BlueStar’s existing digital coaching capabilities, which guide dietary and lifestyle decisions and assist individuals in self-managing their diabetes.

REGULATORY FDA

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 15,2023

Welldoc Receives 10th 510(k) Clearance from FDA for Award-Winning Diabetes Platform BlueStar

Welldoc today announced the receipt of its 10th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar. This clearance reinforces Welldoc’s position as a leader in technology in diabetes management. This 10th 510(k) clearance enables BlueStar to use connected insulin dosing data in personalized bolus insulin dosing recommendations. This enhanced functionality will be made available commercially in 2024.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 21,2023

North America Diabetes Care Devices Market Revenues to Reach USD 35.02 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence

According to a new market research report titled "North America Diabetes Care Devices Market Report (2023-2028)," the market is estimated at USD 25.91 billion in 2023. It is expected to register a CAGR of 6.21% during the forecast period.

View Analyst & Ambassador Comments
Go to original news
Aug 22,2023

Continuous Glucose Monitoring Devices Market Size & Share to Surpass $12.39 Billion by 2030

According to a research publisher, the Global Continuous Glucose Monitoring Devices Market is projected to reach a value of USD 12.39 Billion by 2030 and is expected to exhibit a CAGR of 10.60% from 2023 to 2030. The global Continuous Glucose Monitoring Devices Industry is valued at USD 5.53 Billion in 2022.

View Analyst & Ambassador Comments
Go to original news
Aug 23,2023

Global Blood Glucose Monitoring System Market Size to Reach USD 27.26 Billion in 2032

The projected size of the global market for blood glucose monitoring systems is anticipated to achieve USD 27.26 billion by the year 2032. This projection aligns with a consistent compound annual growth rate (CAGR) of 8.0% during the outlined forecast period, according to the research publisher.

View Analyst & Ambassador Comments
Go to original news
Aug 04,2023

A Complete Guide to Healthy Lifestyle Interventions with Nutrisense

The Nutrisense article discusses healthy lifestyle interventions and how their solution can support them. It covers various aspects such as nutrition, exercise, social support, and sleep hygiene. Nutrisense provides personalized dietary guidance through nutrition coaching, helps monitor glucose response to exercise, offers a supportive community, and tracks sleep patterns. The article emphasizes setting achievable goals, monitoring blood sugar levels with a continuous glucose monitor (CGM), maintaining motivation, and engaging with Nutrisense's support for overall well-being.

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 17,2023

Nemaura Medical Announces SFDA Approval of sugarBEAT®

Nemaura Medical, a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announced SFDA (Saudi Food and Drug Authority) approval of sugarBEAT®, its non-invasive wearable glucose sensor. The news comes following over a year of liaisons with the SFDA through TPMENA, the Company’s licensee in the Middle East. The Company previously announced the receipt of a provisional purchase order for 1.7 million sensors and 17,000 devices from TPMENA. They will now work with its licensee to commence fulfilling this purchase order.

REGULATORY SFDA

#cgm

View Analyst & Ambassador Comments
Go to original news

Mobile Diabetes Management Applications: Downloads & Services

Summary

This expert-led presentation on the downloads and the services provided by the mobile diabetes management applications with highest downloads sheds light on the most downloaded 27 mobile diabetes applications over the last 12 months, takes a deeper look at what is offered in the apps, and finally defines what are the common features and services among the most downloaded applications in the digital diabetes market.

Author: Melis Ince, Senior Market Analyst and Consultant at Research2Guidance

Subscribe to DIABETES